Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-12-28
2008-12-02
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S400000, C514S561000, C514S562000, C514S674000
Reexamination Certificate
active
07459446
ABSTRACT:
Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.
REFERENCES:
patent: 3791988 (1974-02-01), Dieter
patent: 4323558 (1982-04-01), Nelson
patent: 4374829 (1983-02-01), Harris et al.
patent: 4410541 (1983-10-01), Kamimae et al.
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4866090 (1989-09-01), Hoffman et al.
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5077313 (1991-12-01), Lubec
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5366505 (1994-11-01), Farber
patent: 5387109 (1995-02-01), Ishikawa et al.
patent: 5420120 (1995-05-01), Boltralik
patent: 5811446 (1998-09-01), Thomas
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5834032 (1998-11-01), Song
patent: 5852009 (1998-12-01), Cerami et al.
patent: 5854271 (1998-12-01), Thomas et al.
patent: 5906996 (1999-05-01), Murphy
patent: 5972985 (1999-10-01), Thomas et al.
patent: 5980914 (1999-11-01), Gerolymatos
patent: 6147070 (2000-11-01), Facchini
patent: 6309380 (2001-10-01), Larson et al.
patent: 6329414 (2001-12-01), Thomas et al.
patent: 6348465 (2002-02-01), Baker
patent: 6576672 (2003-06-01), Murphy
patent: 6610693 (2003-08-01), Baker
patent: 6821954 (2004-11-01), Reid et al.
patent: 6855511 (2005-02-01), Baker
patent: 6884575 (2005-04-01), Cooper et al.
patent: 6897243 (2005-05-01), Baker et al.
patent: 6951890 (2005-10-01), Cooper et al.
patent: 2002/0034775 (2002-03-01), Baker
patent: 2003/0013772 (2003-01-01), Murphy et al.
patent: 2003/0045506 (2003-03-01), Baker
patent: 2003/0055003 (2003-03-01), Bar-Or et al.
patent: 2003/0055113 (2003-03-01), Wang et al.
patent: 2003/0139312 (2003-07-01), Caswell
patent: 2003/0166561 (2003-09-01), Cooper et al.
patent: 2003/0186946 (2003-10-01), Cooper et al.
patent: 2003/0203973 (2003-10-01), Cooper et al.
patent: 2003/0232799 (2003-12-01), Wang et al.
patent: 2004/0019087 (2004-01-01), Ternansky et al.
patent: 2004/0023854 (2004-02-01), Cooper et al.
patent: 2004/0038861 (2004-02-01), Cooper et al.
patent: 2004/0076603 (2004-04-01), Peled et al.
patent: 2004/0142393 (2004-07-01), Cooper et al.
patent: 2004/0259945 (2004-12-01), Brewer et al.
patent: 2005/0002876 (2005-01-01), Yukl et al.
patent: 2005/0009760 (2005-01-01), Wang et al.
patent: 2005/0031651 (2005-02-01), Gervais et al.
patent: 2005/0047998 (2005-03-01), Cooper et al.
patent: 2005/0074756 (2005-04-01), Cooper et al.
patent: 2005/0085555 (2005-04-01), Murphy et al.
patent: 2005/0159364 (2005-07-01), Cooper et al.
patent: 2005/0159489 (2005-07-01), Baker et al.
patent: 3217071 (1983-11-01), None
patent: 2192789 (1988-01-01), None
patent: 2192790 (1988-01-01), None
patent: 0331014 (1989-02-01), None
patent: 0426066 (1991-05-01), None
patent: 0 576 838 (1994-01-01), None
patent: 1234585 (2002-08-01), None
patent: 7118148 (1995-05-01), None
patent: 2000204037 (2000-07-01), None
patent: 202419 (1979-12-01), None
patent: WO 8201804 (1982-05-01), None
patent: WO 85/04169 (1985-09-01), None
patent: WO 87-05505 (1987-09-01), None
patent: WO 95/11690 (1995-05-01), None
patent: WO 95/17900 (1995-07-01), None
patent: WO 96/12483 (1996-05-01), None
patent: WO 9840071 (1998-09-01), None
patent: WO 99/39712 (1999-08-01), None
patent: WO 9945907 (1999-09-01), None
patent: WO 00/18392 (2000-04-01), None
patent: WO 00/18891 (2000-04-01), None
patent: WO0078805 (2000-12-01), None
patent: 02/43722 (2002-06-01), None
patent: WO0279785 (2002-10-01), None
patent: WO03045424 (2003-06-01), None
patent: WO03062275 (2003-07-01), None
patent: WO03063880 (2003-08-01), None
patent: WO 03/075910 (2003-09-01), None
patent: WO 03/077901 (2003-09-01), None
patent: WO03074559 (2003-09-01), None
patent: WO 03082259 (2003-10-01), None
patent: WO03093311 (2003-11-01), None
patent: 03/099223 (2003-12-01), None
patent: WO2004012760 (2004-02-01), None
patent: WO2004012761 (2004-02-01), None
patent: WO2004017956 (2004-03-01), None
patent: WO2004017957 (2004-03-01), None
patent: WO2004056861 (2004-07-01), None
patent: WO2004065614 (2004-08-01), None
patent: WO2004083215 (2004-09-01), None
patent: WO2004087160 (2004-10-01), None
patent: WO2005040205 (2005-05-01), None
patent: WO2005058294 (2005-06-01), None
Medline Abstract No. 97217050, Kumar, Indian Journal of Experimental Biology, (May 1996) 34(5), 391-402.
Medline Abstract No. 96432582, Oka et al., Japanese Journal of Pharmacology, (Jun. 1996) 71(2), 89-100.
Medline Abstract No. 97074593, Smith et al., CA: A Cancer Journal for Clinicians, (Nov.-Dec. 1996), 46(6), 343-63.
Medline Abstract No. 1998029329, Rickels et al., Journal of Clinical Psychiatry, (1997) 58 Suppl. 11, 4-10.
Harrison's Principles of Internal Medicine, 13th Ed., vol. 1, published 1994 by McGraw-Hill, Inc. (NY), pp. 1108-1116.
The Merck Manual of Diagnosis and Therapy, 14th Ed., published 1982 by Merck, Sharp & Dohme Research Laboratories (NJ), pp. 386-389 and 1036-1053.
American Diabetes Association. (1997). “Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus”, Diabetes Care 20:1183.
American Diabetes Association. (1998). “Economic Consequences of Diabetes Mellitus in the U.S. in 1997”, Diabetes Care 21(2):296-309.
Anaja, (1997). “Diagnostic performance of red cell sorbitol assay in a Nigerian teaching hospital”, Clinica Chimica Acta. 262:1.
Baker, et al. (1993). “Mechanism of fructosamine assay: evdence against role of superoxide as intermediate in nitroblue tetrazolium reduction”. Clin Chem. 39(12):2460.
Barthelmebs, M. et al. (1990). “L-Dopa and Streptozotocin-Induced Diabetic Nephropathy in Rats”,American Journal of Hypertension3(6) Part 2:72S-74S.
Barthelmebs, M. et al. (1991). “Effects of Dopamine Pro-drugs and Fenoldopam on Glomerular Hyperfiltration in Streptozotocin-Induced Diabetes in Rats”,Journal of Cardiovascular Pharmacology18(2):243-253.
Barthlmebs, M. et al. (1995). “Pathophysiological Role of Dopamine in the Kidney: Effects in Diabetes Mellitus and after Contralateral Nephrectomey”,Hypertens. Res. 18(Suppl. I):S131-S136.
Baynes, J. W. (1991). “Role of Oxidative Stress in Development of Complications in Diabetes”, Diabetes 40:405-412.
Boiadzhieva, N. (1990) “The Effect of Dopaminergic Pharmocological Agents on the Pancreatic Islet Apparatus in Rats”,Eksp Med Morfol29(3):20-26. (English abstract).
Borgstrom, L. et al. (1986). “Pharmacokinetics of N-Acetylcysteine in Man”,Eur J Clin Pharmacol31:217-222.
Chan, P.C. and Bielski, B.H.J. (1974) “Enzyme-catalyzed Free Radical Reactions with nicotinamide Adenine Nucleotides”,J Biol Chem249(4):1317-1319.
Chan, P.C. and Bielski, B.H.J. (1980). “Glyceraldehyde-3-Phosphate Dehydrogenase-catalyzed Chain Oxidation of Reduced Nicotinamide Adenine Dinucleotide by Perhydroxyl Radicals”,J Biol chem255(3):874-876.
Chaturvedi, N. et al. (1998). “Effect of Lisinopril on Progression of Retinopathy in Normotensive People with Type 1 Diabetes”,The Lancet351:28-31.
Dahlman, et al., (2000). “Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine),”, YJM 9=88(9):609-616.
Deckert T. et al. (1978). “Prognosis of Diabetics with Diabetes Onset before the Age of Thirtyone”,Diabetologia14:363-370.
Dubois, R.S. et al. (1970). “Triethylene Teramine Dihydrochloride in Wilson's Disease”,Lancet2(7676):775.
Duchin, K.L. et a. (1988). “Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases”,Clin Pharmacokinetics14:241-259.
Elstner, E.f. and Heupel, A. (1976). “Inhibition of Nitrite Formation from Hydroxylammonium-chloride: A Simple Assay for Superoxide Dismutase”,Anal Biochem70:616-620.
Epstein, O. and Sherlock, S. (1980). “Triethylene Tetramine Dihydrochloride Toxicity in Primary Biliary Cirrhosis”,Gastroenterology78(6):1442-1445.
Chiara et al:
Baker John Richard
Cooper Garth J. S.
LandOfFree
Treatment of diabetes with copper binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diabetes with copper binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes with copper binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032285